Home / Library / HCV Treatment in 2016: Genotypes 1, 2, and 3

HCV Treatment in 2016: Genotypes 1, 2, and 3

Publish date: October 12, 2016

AETC source: Southeast AETC

Objectives

  • List available HCV direct acting antivirals (DAAs) available for HCV therapy in 2016
  • Describe appropriate HCV DAA therapies for HCV genotypes 1, 2, and 3
  • Evaluate the potential for DAA drug-drug interactions, particularly with HIV antiretroviral therapy.

Presented by:

Cody Chastain, MD
Assistant Professor, Viral Hepatitis Program
Vanderbilt University School of Medicine, Division of Infectious Diseases

Check all that apply
Check all that apply
By submitting this form, you accept the Mollom privacy policy.

Browse more

Language: English

Topic(s): Antiretroviral Therapy, Drug Interactions, OIs & Comorbid Conditions, Comorbidities, Coinfections, & Complications, Viral Hepatitis Coinfection

Resource type: Online and Self-Paced Learning

Add comment

Log in to post comments